Merck BioVentures: where biosimilars make a difference
This article was originally published in Scrip
Mike Kamarck, the president of Merck BioVentures, tells ScripIntelligence Managing Editor, John Hodgson, how pharma companies are shaping the biosimilars rules in the US, why Merck switched from biobetters to biosimilars, and why Enbrel is a good place to start a biosimilars business.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.